caa a22 4500 469074450 CHVBK 20180323132931.0 cr unu---uuuuu 170328e19920901xx s 000 0 eng 10.1007/BF01741552 doi (NATIONALLICENCE)springer-10.1007/BF01741552 Persistent measles virus infection enhances major histocompatibility complex class I expression and immunogenicity of murine neuroblastoma cells [Elektronische Daten] [Jacob Gopas, Dganit Itzhaky, Yael Segev, Samuel Salzberg, Barry Trink, Noah Isakov, Bracha Rager-Zisman] The effect of persistent measles virus infection on the expression of major histocompatibility complex (MHC) class I antigens was studied. Mouse neuroblastoma cells C1300, clone NS20Y, were persistently infected with the Edmonston strain of measles virus. The persistently infected cell line, NS20Y/MS, expressed augmented levels of both H-2Kk and H-2Dd MHC class I glycoproteins. Activation of two interferon(IFN)-induced enzymes, known to be part of the IFN system: (2′-5′)oligoadenylate synthetase and double-stranded-RNA-activated protein kinase, was detected. Measles-virus-infected cells elicited cytotoxic T lymphocytes that recognized and lysed virus-infected and uninfected neuroblastoma cells in an H-2-restricted fashion. Furthermore, immunization of mice with persistently infected cells conferred resistance to tumor growth after challenge with the highly malignant NS20Y cells. The rationale for using measles virus for immunotherapy is that most patients develop lifelong immunity after recovery or vaccination from this infection. Patients developing cancer are likely to have memory cells. A secondary response induced by measles-virus-infected cells may therefore induce an efficient immune response against non-infected tumour cells. Springer-Verlag, 1992 MHC class I nationallicence Measles virus nationallicence Tumor immunogenicity nationallicence Gopas Jacob Department of Microbiology and Immunology, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel aut Itzhaky Dganit Department of Microbiology and Immunology, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel aut Segev Yael Department of Microbiology and Immunology, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel aut Salzberg Samuel Department of Life Sciences, Bar-Ilan University, Ramat Gan, Israel aut Trink Barry Department of Life Sciences, Bar-Ilan University, Ramat Gan, Israel aut Isakov Noah Department of Microbiology and Immunology, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel aut Rager-Zisman Bracha Department of Microbiology and Immunology, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel aut Cancer Immunology, Immunotherapy Springer-Verlag 34/5(1992-09-01), 313-320 0340-7004 34:5<313 1992 34 262 https://doi.org/10.1007/BF01741552 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF01741552 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Gopas Jacob Department of Microbiology and Immunology, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel aut NATIONALLICENCE 700 1- Itzhaky Dganit Department of Microbiology and Immunology, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel aut NATIONALLICENCE 700 1- Segev Yael Department of Microbiology and Immunology, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel aut NATIONALLICENCE 700 1- Salzberg Samuel Department of Life Sciences, Bar-Ilan University, Ramat Gan, Israel aut NATIONALLICENCE 700 1- Trink Barry Department of Life Sciences, Bar-Ilan University, Ramat Gan, Israel aut NATIONALLICENCE 700 1- Isakov Noah Department of Microbiology and Immunology, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel aut NATIONALLICENCE 700 1- Rager-Zisman Bracha Department of Microbiology and Immunology, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel aut NATIONALLICENCE 773 0- Cancer Immunology, Immunotherapy Springer-Verlag 34/5(1992-09-01), 313-320 0340-7004 34:5<313 1992 34 262 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer